Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells.

Gravett, A M; Trautwein, N; Stevanovic, S; Dalgleish, A G; Copier, J

Gravett, A M; Trautwein, N; Stevanovic, S; Dalgleish, A G; Copier, J.

Afiliação

Gravett AM; Institute for infection and immunity, St George's, University of London, London, UK.
Trautwein N; Department of Immunology, Institute of Cell Biology, University of Tübingen, Tübingen, Germany.
Stevanovic S; Department of Immunology, Institute of Cell Biology, University of Tübingen, Tübingen, Germany.
Dalgleish AG; Institute for infection and immunity, St George's, University of London, London, UK.
Copier J; Institute for infection and immunity, St George's, University of London, London, UK.

Oncoimmunology ; 7(6): e1438107, 2018.

Article em En | MEDLINE | ID: mdl-29930882

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: Oncoimmunology Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google